Ignite Creation Date:
2025-12-24 @ 3:06 PM
Ignite Modification Date:
2025-12-27 @ 9:12 PM
Study NCT ID:
NCT05248659
Status:
ENROLLING_BY_INVITATION
Last Update Posted:
2024-12-09
First Post:
2022-02-18
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Phase 2/3 Open-Label Trial of Sibeprenlimab in the Treatment of Immunoglobulin A Nephropathy
Sponsor:
Otsuka Pharmaceutical Development & Commercialization, Inc.
Organization:
Organization Data
Organization:
Class:
INDUSTRY
Study ID:
417-201-00012
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
INDUSTRY
Responsible Party:
Responsible Party Title:
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
Old Name:
None
Old Organization:
None